Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Fulcrum Therapeutics Q1 2024 GAAP EPS $(0.43) Beats $(0.44) Estimate

Author: Benzinga Newsdesk | May 13, 2024 07:01am
Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.44) by 2.27 percent.

Posted In: FULC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist